Search results for "Peroxisome proliferator"

showing 10 items of 132 documents

Pioglitazone Reduces Secondary Brain Damage after Experimental Brain Trauma by PPAR-γ-Independent Mechanisms

2011

Inflammatory and ischemic processes contribute to the development of secondary brain damage after mechanical brain injury. Recent data suggest that thiazolidinediones (TZDs), a class of drugs approved for the treatment of non-insulin-dependent diabetes mellitus, effectively reduces inflammation and brain lesion by stimulation of the peroxisome proliferator-activated receptor-γ (PPAR-γ). The present study investigates the influence of the TZD pioglitazone and rosiglitazone on inflammation and secondary brain damage after experimental traumatic brain injury (TBI). A controlled cortical impact (CCI) injury was induced in male C57BL/6 mice to investigate following endpoints: (1) mRNA expression…

Malemedicine.medical_specialtyTraumatic brain injuryPeroxisome proliferator-activated receptorInflammationStimulationBrain damageMiceDiabetes mellitusInternal medicinemedicineAnimalsHypoglycemic Agentschemistry.chemical_classificationPioglitazonebusiness.industrymedicine.diseaseMice Inbred C57BLPPAR gammaDisease Models AnimalNeuroprotective AgentsEndocrinologychemistryBrain InjuriesBrain Damage ChronicThiazolidinedionesNeurology (clinical)medicine.symptombusinessRosiglitazonePioglitazonemedicine.drugJournal of Neurotrauma
researchProduct

Relationship between endocrine disruptors and obesity with a focus on bisphenol A: a narrative review

2021

International audience; Introduction: Scientific data suggest that early exposure to endocrine-disrupting chemicals (EDCs) affect -repro, -neuro, -metabolic systems, to which are added other notions such as mixtures, window and duration of exposure, trans-generational effects, and epigenetic mechanisms. Methods: In the present narrative review, we studied the relationship between exposure to EDCs with the appearance and development of obesity. Results: Exposure to EDCs like Bisphenol A during the early stages of development has been shown to lead to weight gain and obesity. EDCs can interfere with endocrine signaling, affect adipocytes differentiation and endocrine function and disrupt meta…

Medicine (General)obesityFuture studiesQH301-705.5bisphenol APharmaceutical Science030209 endocrinology & metabolismReviewBiologyBioinformaticsadipocyteGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineR5-920medicineEndocrine systemmetabolic disordersEpigeneticsBiology (General)030304 developmental biology0303 health sciencesfat tissuesLow doseGeneral Medicine[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesmedicine.diseaseObesity3. Good healthperoxisome proliferator-activated receptor-γNarrative review
researchProduct

Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis.

2001

Peroxisome proliferators, which function as peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists, are a group of structurally diverse nongenotoxic hepatocarcinogens including the fibrate class of hypolipidemic drugs that induce peroxisome proliferation in liver parenchymal cells. Sustained activation of PPARalpha by these agents leads to the development of liver tumors in rats and mice. To understand the molecular mechanisms responsible for the pleiotropic effects of these agents, we have utilized the cDNA microarray to generate a molecular portrait of gene expression in the liver of mice treated for 2 weeks with Wy-14,643, a potent peroxisome proliferator. PPARalpha activa…

Mice KnockoutPeroxisome proliferator-activated receptor gammaDNA ComplementaryChemistryMicroarray analysis techniquesGene Expression ProfilingPeroxisome ProliferationReceptors Cytoplasmic and NuclearPeroxisomeArticleCell biologyGene expression profilingMice Inbred C57BLMicePyrimidinesLiverGene expressionGeneticsAnimalsPeroxisome proliferator-activated receptor deltaPeroxisome proliferator-activated receptor alphaMolecular BiologyOligonucleotide Array Sequence AnalysisTranscription FactorsGene expression
researchProduct

Astrocytes Protect Neurons from Aβ1-42 Peptide-Induced Neurotoxicity Increasing TFAM and PGC-1 and Decreasing PPAR-γ and SIRT-1

2015

One of the earliest neuropathological events in Alzheimer's disease is accumulation of astrocytes at sites of Aβ1-42 depositions. Our results indicate that Aβ1-42 toxic peptide increases lipid peroxidation, apoptosis and cell death in neurons but not in astrocytes in primary culture. Aβ1-42-induced deleterious neuronal effects are not present when neurons and astrocytes are mixed cultured. Stimulation of astrocytes with toxic Aβ1-42 peptide increased p-65 and decreased IκB resulting in inflammatory process. In astrocytes Aβ1-42 decreases protein expressions of sirtuin 1 (SIRT-1) and peroxisome proliferator-activated receptor γ (PPAR-γ) and over-expresses peroxisome proliferator-activated re…

MnSODProgrammed cell deathPPAR-γPeroxisome proliferator-activated receptorMitochondrionBiologyBioinformaticsmedicine.disease_causeAlzheimer's DiseaseNeurologiaPGC-1Sirtuin 1medicineAnimalsTFAMCells Culturedchemistry.chemical_classificationNeuronsAmyloid beta-PeptidesCell DeathSirtuin 1Caspase 3Superoxide DismutaseNeurotoxicityTranscription Factor RelAGeneral MedicineTFAMmedicine.diseasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaCoculture TechniquesPeptide FragmentsCell biologyMitochondriaPeroxidesRatsPPAR gammachemistryMitochondrial biogenesisNF-κB.Astrocytesbiology.proteinFisiologia humanaLipid PeroxidationOxidative stressResearch PaperTranscription FactorsInternational Journal of Medical Sciences
researchProduct

PPAR-γ Agonist GW1929 But Not Antagonist GW9662 Reduces TBBPA-Induced Neurotoxicity in Primary Neocortical Cells

2013

Tetrabromobisphenol A (2,2-bis(4-hydroxy-3,5-dibromophenyl)propane; TBBPA) is a widely used brominated flame retardant. TBBPA induces neuronal damage, but the mechanism by which this occurs is largely unknown. We studied the possible involvement of peroxisome proliferator-activated receptor gamma (PPAR-γ) in TBBPA-induced apoptosis and toxicity in mouse primary neuronal cell cultures. TBBPA enhanced both, caspase-3 activity and lactate dehydrogenase (LDH) release in neocortical cells after 6 and 24 h of exposition. These data were supported at the cellular level with Hoechst 33342 staining. Immunoblot analyses showed that, compared with control cells, 10 μM TBBPA decreased the expression of…

PPAR-γTime FactorsNeuroscience(all)Polybrominated BiphenylsPeroxisome proliferator-activated receptorGW1929Caspase 3ApoptosisNeocortexPharmacologyBiologyToxicologyNeuroprotectionBenzophenonesMicemedicineNeurotoxicityAnimalsAnilidesReceptorCells Culturedchemistry.chemical_classificationNeuronsDose-Response Relationship DrugL-Lactate DehydrogenaseCaspase 3General NeuroscienceNeurotoxicityApoptotic bodymedicine.diseasePPAR gammaTBBPANeuroprotective AgentschemistryCell cultureApoptosisTyrosineNeurotoxicity SyndromesOriginal ArticleCentral Nervous System AgentsNeurotoxicity Research
researchProduct

Myoglobin, expressed in brown adipose tissue of mice, regulates the content and activity of mitochondria and lipid droplets

2021

Abstract The identification of novel physiological regulators that stimulate energy expenditure through brown adipose tissue (BAT) activity in substrate catalysis is of utmost importance to understand and treat metabolic diseases. Myoglobin (MB), known to store or transport oxygen in heart and skeletal muscles, has recently been found to bind fatty acids with physiological constants in its oxygenated form (i.e., MBO2). Here, we investigated the in vivo effect of MB expression on BAT activity. In particular, we studied mitochondrial function and lipid metabolism as essential determinants of energy expenditure in this tissue. We show in a MB-null (MBko) mouse model that MB expression in BAT i…

PalmitatesOxidative phosphorylationMitochondrion1307 Cell BiologyMiceAdipose Tissue BrownLipid dropletBrown adipose tissueRespiration1312 Molecular BiologymedicineAnimalsHumansPPAR alpha11434 Center for Clinical StudiesMuscle SkeletalMolecular BiologyUncoupling Protein 1Mice KnockoutMyoglobinChemistryProteinsThermogenesisLipid metabolismLipid DropletsCell BiologyMetabolism10081 Institute of Veterinary PhysiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaCell biologyOxygenDisease Models AnimalAdipocytes Brownmedicine.anatomical_structure10076 Center for Integrative Human Physiology570 Life sciences; biologyApoptosis Regulatory ProteinsEnergy MetabolismThermogenesisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
researchProduct

The Blood–Brain Barrier as a Target in Traumatic Brain Injury Treatment

2014

Traumatic brain injury (TBI) is one of the most frequent causes of death in the young population. Several clinical trials have unsuccessfully focused on direct neuroprotective therapies. Recently immunotherapeutic strategies shifted into focus of translational research in acute CNS diseases. Cross-talk between activated microglia and blood–brain barrier (BBB) could initiate opening of the BBB and subsequent recruitment of systemic immune cells and mediators into the brain. Stabilization of the BBB after TBI could be a promising strategy to limit neuronal inflammation, secondary brain damage and acute neurodegeneration. This review provides an overview on the pathophysiology of TBI and brain…

Pathologymedicine.medical_specialtyTraumatic brain injuryPeroxisome Proliferator-Activated ReceptorsBrain EdemaInflammationBrain damageBlood–brain barrierNeuroprotectionRosiglitazoneReceptors GlucocorticoidmedicineHumansHypoglycemic AgentsMyosin-Light-Chain KinaseNeuroinflammationInflammationPioglitazoneMicrogliabusiness.industryNeurodegenerationNeurodegenerative DiseasesGeneral Medicinemedicine.diseaseCell HypoxiaNeuroprotective Agentsmedicine.anatomical_structurenervous systemBlood-Brain BarrierBrain InjuriesThiazolidinedionesmedicine.symptombusinessNeuroscienceArchives of Medical Research
researchProduct

The human peroxisome in health and disease: The story of an oddity becoming a vital organelle

2013

Abstract Since the first report by Rhodin in 1954, our knowledge on mammalian microbodies/peroxisomes has known several periods. An initial two decades period (1954–1973) has contributed to the biochemical individualisation of peroxisomes as a new class of subcellular organelles (de Duve, 1965). The corresponding research period failed to define a clear role of mammalian peroxisomes in vital functions and intermediary metabolism, explaining why feeling that peroxisomes might be in the human cell oddities has prevailed during several decades. The period standing from 1973 to nowadays has progressively removed this cell oddity view of peroxisomes by highlighting vital function and metabolic r…

Peroxisome Proliferator-Activated ReceptorsDiseaseBiologyCell FractionationMicrobodiesBiochemistryPeroxisomal DisordersOrganellePeroxisomal disorderCentrifugation Density GradientPeroxisomesmedicineAnimalsHumansMicrobodyZellweger SyndromeOrganelle envelopeFatty AcidsGeneral MedicinePeroxisomeLipid Metabolismmedicine.diseaseCell biologyBiochemistryNuclear receptorMetabolic Networks and PathwaysFunction (biology)Biochimie
researchProduct

Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview.

2021

Abstract Natural products and synthetic analogs have drawn much attention as potential therapeutical drugs to treat metabolic syndrome. We reviewed the underlying mechanisms of 32 natural products and analogs with potential pharmacological effects in vitro, and especially in rodent models and/or patients, that usually act on the PPAR pathway, along with other molecular targets. Recent outstanding total syntheses or semisyntheses of these lead compounds are stated. In general, they can activate the transcriptional activity of PPARα, PPARγ, PPARα/γ, PPARβ/δ, PPARα/δ, PPARγ/δ and panPPAR as weak, partial agonists or selective PPARγ modulators (SPPARγM), which may be useful for managing obesity…

Peroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptorPharmacologyResveratrol01 natural sciences03 medical and health scienceschemistry.chemical_compoundStructure-Activity RelationshipBerberineDrug DiscoverymedicineAnimalsHumansReceptor030304 developmental biologyPharmacologychemistry.chemical_classificationMetabolic Syndrome0303 health sciencesBiological ProductsDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryOrganic ChemistryGeneral MedicinePPAR Pathwaymedicine.disease0104 chemical sciencesCurcuminQuercetinDyslipidemiaEuropean journal of medicinal chemistry
researchProduct

Toxicological evaluation of peroxisome proliferators. Further cellular and molecular aspects.

1996

International audience

Peroxisome proliferatorChemistryGeneral NeuroscienceCell CycleGuinea PigsFibric AcidsPharmacologyMicrobodiesGeneral Biochemistry Genetics and Molecular BiologyRats[SDV.TOX] Life Sciences [q-bio]/ToxicologyClofibric AcidHistory and Philosophy of ScienceLiverSpecies Specificity[SDV.TOX]Life Sciences [q-bio]/ToxicologyAnimalsHumansComputingMilieux_MISCELLANEOUSCells CulturedAnnals of the New York Academy of Sciences
researchProduct